| Dec'19 | Dec'18 | Dec'17 | Dec'16 | |||
|---|---|---|---|---|---|---|
Revenue | ||||||
0 | 0 | 0 | 0 | |||
Operating expenses: | ||||||
Research and development | ||||||
94,737 | 57,965 | 39,905 | 20,116 | |||
General and administrative | ||||||
24,581 | 17,722 | 14,952 | 5,460 | |||
Total operating expenses | ||||||
119,318 | 75,687 | 54,857 | 25,576 | |||
Loss from operations | ||||||
-119,318 | -75,687 | -54,857 | -25,576 | |||
Other income (expense): | ||||||
Revaluation of preferred unit tranche right | ||||||
- | - | 459 | 1,163 | |||
Interest income | ||||||
1,580 | 619 | 219 | 369 | |||
Other income | ||||||
515 | 270 | 1,001 | 271 | |||
Total other income (expense), net | ||||||
2,095 | 889 | 1,679 | 1,803 | |||
Net loss | ||||||
-117,223 | -74,798 | -53,178 | -23,773 | |||
Net loss attributable to non-controlling interest | ||||||
- | 0 | -1,060 | -2,234 | |||
Net loss attributable to Solid Biosciences Inc. | ||||||
-117,223 | -74,798 | -52,118 | -21,539 | |||
Accretion of preferred units to redemption value | ||||||
- | - | 959 | -4,309 | |||
Redemption of preferred units | ||||||
- | - | 15,685 | - | |||
Redemption of redeemable interest from non-controlling interest in Solid GT | ||||||
- | - | 1,925 | - | |||
Net loss attributable to common stockholders | ||||||
-117,223 | -74,798 | -39,317 | -17,230 | |||
Net loss per share attributable to common stockholders, basic and diluted | ||||||
-2.91 | -2.25 | -2.88 | -10.14 | |||
Weighted average shares of common stock outstanding, basic and diluted | ||||||
40,289 | 33,262 | 13,649 | 1,698 | |||